10-Q: Compass Therapeutics Q2 2026: Mixed Clinical Data, Rising Costs

Compass Therapeutics reports increased R&D and G&A expenses in Q2 2026, alongside promising but mixed clinical trial results for its lead candidate, tovecimig.

Summary

• Compass Therapeutics reported a net loss of $25.2 million for the three months ended June 30, 2026, compared to a net loss of $19.9 million for the same period in 2025.
• Total operating expenses increased to $27.0 million in Q2 2026 from $21.1 million in Q2 2025, driven by higher research and development (R&D) and general and administrative (G&A) costs.
• R&D expenses rose 19% to $19.6 million, primarily due to non-personnel project expenses for tovecimig.
• G&A expenses increased 59% to $7.4 million, attributed to pre-commercialization expenses and higher stock-based compensation.
• The company had $180 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which is expected to fund operations into 2028.
• Positive survival and safety data from the COMPANION-002 Phase 2/3 study of tovecimig in biliary tract cancer (BTC) were announced, meeting the primary endpoint for overall response rate (ORR).
• However, overall survival (OS) secondary endpoint analyses were confounded by high crossover rates and did not meet statistical significance.
• Phase 1 expansion cohorts for CTX-8371 are enrolling, with additional data expected in Q4 2026, and the Phase 1 dose-escalation study for CTX-10726 is also enrolling, with clinical data expected in Q4 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to continued net losses and increasing operating expenses, despite positive clinical trial data for tovecimig.

Positives

• The COMPANION-002 Phase 2/3 study of tovecimig in biliary tract cancer met its primary endpoint for overall response rate (ORR) of 18.0% in the tovecimig combination arm versus 5.3% in the control arm.
• The tovecimig combination arm showed a statistically significant improvement in median progression-free survival (PFS) of 4.7 months versus 2.6 months, a 56% reduction in the risk of progression.
• Data from the CTX-8371 Phase 1 study showed an ORR of 33% at the two highest dose levels (3.0 and 10.0 mg/kg) in evaluable patients, with durable responses observed.
• The company has $180 million in cash, cash equivalents, and marketable securities, providing an estimated runway into 2028.
• Two additional investigator-sponsored trials (ISTs) have been initiated for tovecimig in colorectal cancer and glioblastoma.

Negatives

• Net loss for the three months ended June 30, 2026, was $25.2 million, an increase from $19.9 million in the prior year period.
• Total operating expenses increased by 28% to $27.0 million for the three months ended June 30, 2026, compared to $21.1 million in the prior year period.
• General and administrative expenses increased by 59% to $7.4 million for the three months ended June 30, 2026, driven by pre-commercialization expenses and stock-based compensation.
• Overall survival (OS) secondary endpoint analyses in the COMPANION-002 study were confounded and did not meet statistical significance.
• The company has an accumulated deficit of $475 million as of June 30, 2026.
• The company expects to continue incurring significant expenses and requires substantial additional funding.

Risks

• The company operates in the biotechnology and pharmaceutical industries, facing risks related to research and development success, regulatory approval, and commercial viability.
• There is no assurance that the company's research and development will be successfully completed or that any products developed will obtain necessary government regulatory approval or be commercially viable.
• The company is dependent on the services of its employees and consultants.
• The company's second amended and restated bylaws designate specific courts as the sole and exclusive forum for certain stockholder actions, which may limit stockholders' ability to obtain a favorable judicial forum.
• Macroeconomic conditions such as economic downturns, inflation, increased interest rates, and geopolitical events could adversely affect the company's results of operations and financial condition.
• Current or future tariffs could result in increased research and development expenses.
• The company may be unable to raise additional funds or enter into favorable agreements, potentially leading to delays or elimination of development and commercialization efforts.

Future Outlook

The company expects to continue incurring significant expenses for at least the next several years as it advances clinical development, develops additional product candidates, and seeks regulatory approval. It anticipates needing substantial additional funding through equity and debt financings, or other capital sources. The company expects its current cash resources to fund operating expenses and capital expenditure requirements into 2028.

Management Comments

• "We expect feedback from the FDA in the third quarter regarding the COMPANION-002 Phase 2/3 data, prior to a potential BLA filing later this year."
• "The tovecimig combination arm also demonstrated a highly statistically significant improvement versus paclitaxel alone in the secondary endpoint of median progression-free survival (PFS) of 4.7 months versus 2.6 months, providing a 56% reduction in the risk of progression."
• "We expect that such cash resources will enable us to fund our operating expenses and capital expenditure requirements into 2028."
• "We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all."

Industry Context

StockSavvy.ai notes that Compass Therapeutics operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical sector, where success is heavily reliant on clinical trial outcomes, regulatory approvals, and substantial funding. The company's focus on oncology and novel antibody-based therapeutics aligns with current industry trends, but the path to commercialization is fraught with significant risks and requires continuous investment.

Comparison to Industry Standards

• The net loss of $25.2 million for the quarter and $43.5 million for the six months is consistent with clinical-stage biopharmaceutical companies that are heavily investing in R&D without product revenue.
• The increase in R&D expenses to $19.6 million for the quarter is in line with companies advancing multiple candidates through clinical trials.
• The company's cash runway into 2028, with $180 million in cash, cash equivalents, and marketable securities, is a critical factor for its continued operations and development, comparable to other companies at a similar stage requiring significant future funding.
• The positive ORR and PFS results for tovecimig in BTC, while promising, need to be viewed in the context of the overall survival data being confounded, a common challenge in oncology trials with high crossover rates.

Corporate Governance

Legal Proceedings

• As of the date of this report, the company is not involved in any material legal proceedings.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financings, potential limitations on legal recourse due to forum selection clauses, and continued uncertainty regarding profitability and commercialization success.
• Employees: Continued investment in R&D and potential future commercialization efforts may lead to growth and opportunities, but also risks associated with funding and development timelines.
• Creditors: The company's ability to meet its obligations depends on its ability to secure future funding.

Next Steps

• Expect feedback from the FDA in the third quarter regarding the COMPANION-002 Phase 2/3 data, prior to a potential BLA filing later this year.
• Additional data from CTX-8371 Phase 1 cohort expansions are expected in the fourth quarter of 2026.
• Clinical data from the CTX-10726 Phase 1 dose-escalation cohort is expected in the fourth quarter of 2026.
• Evaluate additional studies for tovecimig in other indications, including both ISTs and Company-sponsored studies.
• Continue advancing product candidates through clinical development as standalone therapies and in combination.

Key Dates

Recommendation

The company shows promising clinical data for its lead candidate, tovecimig, and has a sufficient cash runway into 2028. However, the continued net losses, increasing operating expenses, and the confounding of overall survival data in a key trial temper enthusiasm. The need for substantial future funding and the inherent risks in drug development warrant a cautious 'hold' stance until further clinical and regulatory milestones are achieved.

Keywords

oncology, biopharmaceutical, tovecimig, CTX-8371, CTX-10726, clinical-stage, drug development, biliary tract cancer